$9.00
-0.68-7.02%
Pre-Market: 9:24 AM EDT
Comments
Loading...
Latest Mineralys Therapeutics Stock News | NASDAQ:MLYS | Benzinga
Get the latest news on Mineralys Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Mineralys Therapeutics performance
Categories: All
Monday, February 24, 2025
Thursday, February 13, 2025
Wednesday, February 12, 2025
Thursday, February 06, 2025
Tuesday, February 04, 2025
Wednesday, January 29, 2025
Friday, January 24, 2025
Wednesday, January 08, 2025
Tuesday, November 12, 2024
Monday, November 11, 2024
Friday, November 08, 2024
Thursday, October 31, 2024
Wednesday, October 30, 2024
Wednesday, September 25, 2024
Thursday, August 15, 2024
Wednesday, August 14, 2024
Tuesday, August 13, 2024
Wednesday, July 10, 2024
Thursday, May 09, 2024
Tuesday, April 02, 2024
Thursday, March 21, 2024
Wednesday, March 20, 2024
Thursday, February 08, 2024
- Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Mineralys Therapeutics shares are trading hig...
- Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
- Mineralys Therapeutics Announces $120M Privat...
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Friday, December 22, 2023
Thursday, December 21, 2023
Saturday, November 11, 2023
Tuesday, November 07, 2023
Thursday, November 02, 2023
Tuesday, October 03, 2023
Monday, September 11, 2023
Sunday, September 10, 2023
- Mineralys Therapeutics Announced Target-htn Successfully Met Its Primary Endpoint; Key Secondary Endpoint Results Demonstrated A Change In Diastolic Aobp Of -7.1 Mmhg With 50mg
- Mineralys Therapeutics Announced JAMA Publication Of Full Target-HTN Phase 2 Trial Results for Lorundrostat In Uncontrolled and Treatment-Resistant Hypertension